NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.

6 brokerages have issued twelve-month price objectives for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

News coverage about DOVA stock has trended positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Dova Pharmaceuticals.

Dova Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totalling 572,700 shares, a drop of 51.9% from the October 31st total of 1,190,000 shares. Based on an average trading volume of 587,400 shares, the days-to-cover ratio is presently 1.0 days. Approximately 4.4% of the shares of the stock are sold short. View Dova Pharmaceuticals' Current Options Chain.

Some companies that are related to Dova Pharmaceuticals include HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Myokardia (MYOK), PTC Therapeutics (PTCT), Genmab A/S (GMAB), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA) and Xencor (XNCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), Fate Therapeutics (FATE), Heron Therapeutics (HRTX), TESARO (TSRO), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Allena Pharmaceuticals (ALNA).

(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Dova Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (1.15%), State Street Corp (0.66%), Gabelli Funds LLC (0.26%), Millennium Management LLC (0.18%), GABELLI & Co INVESTMENT ADVISERS INC. (0.11%) and Virtu Financial LLC (0.07%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

DOVA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp and Barclays PLC. Company insiders that have sold Dova Pharmaceuticals company stock in the last year include David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Mark W Hahn and Roger Jeffs. View Insider Buying and Selling for Dova Pharmaceuticals.

DOVA stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Virtu Financial LLC, Tower Research Capital LLC TRC and Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]